Featured Posts
Recent Posts
Please reload

Peter Speaks with Jo Eames at the Action Duchenne Conference

January 16, 2018

1/10
Please reload

SPINRAZA APPROVED by EMA for all types of SMA

April 21, 2017

After receiving approval from the FDA in the United States, the long awaited treatment for spinal muscular atrophy (SMA) has been approved for use in Europe.

The EMA has granted a license for use in all types of 5q SMA. Now families and charities such as Muscular Dystrophy UK will be pushing for the needed decisions from NICE & NHS England as well as the Scottish Medicines Consortium and the Health and Social care board in Northern Ireland to make Spinraza available to all with SMA in the U.K.

 

Here is the full press release from the European Medicines Agency in London:

On 21 April 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Spinraza, intended for the treatment of 5q spinal muscular atrophy (SMA).

Spinraza, which was designated as an orphan medicinal product on 2 April 2012, was reviewed under EMA’s accelerated assessment programme.

The applicant for this medicinal product is Biogen Idec Ltd. Spinraza will be available as a 2.4 mg/ml solution for injection. The active substance of Spinraza is nusinersen, an antisense oligonucleotide (ATC code: N07) that can make the SMN2 gene produce adequate levels of full-length SMN protein, thus improving neuronal survival.

The benefits with Spinraza are its ability to allow achievement of motor milestones and improvement in muscle function which is not observed during the natural course of the disease. The most common side effects are related to its administration via lumbar puncture.

The full indication is: "Spinraza is indicated for the treatment of 5q spinal muscular atrophy." It is proposed that Spinraza should only be started by a physician with experience in the management of spinal muscular atrophy.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

 

 

Please reload

Archive
Please reload

Search By Tags